Intravitreal bevacizumab for pseudophakic cystoid macular edema; a systematic review

Journal of Ophthalmic and Vision Research

Volumn 7, Issue 3, 2012, Pages 235-239

  Falavarjani, Khalil Ghasemi ^a   Parvaresh, Mohammad Mehdi ^a   Modarres, Mehdi ^a   Hashemi, Masih ^a   Samiy, Nasrollah ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Retina Institute of the Carolinas   (United States)

Author keywords

Bevacizumab anti vascular endothelial growth factor; Cataract surgery; Cystoid macular edema; Intravitreal injection

Indexed keywords

EID: 84867774800     PISSN: 20082010     EISSN: 2008322X     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Irvine SR. A newly defined vitreous syndrome following cataract surgery; interpreted according to recent concepts of the structure of the vitreous; the Seventh Francis I. Proctor Lecture. Am J Ophthalmol 1953;36:599-619.
2. Spaide RF, Yannuzzi LA, Sisco LJ. Chronic cystoids macular edema and predictors of visual acuity. Ophthalmic Surg 1993;24:262-267.
3. Levin DS, Lim JI. Update on pseudophakic cystoids macular edema treatment options. Ophthalmol Clin North Am 2002;15:467-472.
4. Benitah NR, Arroyo JG. Pseudophakic cystoids macular edema. International Ophthalmol Clin 2010;50:139-153.
5. Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema; risk factors for development and duration after treatment. J Cataract Refract Surg 2007;33:1550-1558.
6. Jacobson DR, Dellaporta A. Natural history of cystoid macular edema after cataract extraction. Am J Ophthalmol 1974;77:445-447.
7. Miyake K, Ibaraki N. Prostaglandins and cystoids macular edema. Surv Ophthalmol 2002;47:S203-S218.
8. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002;133:373-385.
9. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
10. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
11. Modarres M, Naseripour M, Falavarjani KG, Nikeghbali A, Hashemi M, Parvaresh MM. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD. Retina 2009;29:319-324.
12. Modarres M, Nazari H, Falavarjani KG, Naseripour M, Hashemi M, Parvaresh MM. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2009;19:848-852.
13. Falavarjani KG, Modarres M, Nazari H. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy. Eye (Lond) 2010;24:717-719.
14. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion; a short-term study. Retina 2006;26:279-284.
15. Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina 2010;30:260-266.
16. Arevalo JF, Maia M, Garcia-Amaris RA, Roca JA, Sanchez JG, Berrocal MH, et al. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology 2009;116:1481-1487.
17. Spitzer MS, Ziemssen F, Yoeruek E, Petermeier K, Aisenbrey S, Szurman P. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg 2008;34:70-75.
18. Arevalo JF, Garcia-Amaris RA, Roca JA, Sanchez JG, Wu L, Berrocal MH, et al. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. J Cataract Refract Surg 2007;33:2098-2105.
19. Barone A, Russo V, Prascina F, Delle Noci N. Shortterm safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema. Retina 2009;29:33-37.
20. Díaz-Llopis M, Amselem L, Cervera E, García-Delpech S, Torralba C, Montero J. Intravitreal injection of bevacizumab for pseudophakic cystoid macular edema resistant to steroids. Arch Soc Esp Oftalmol 2007;82:447-450.
21. Mason JO 3rd, Albert MA Jr, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 2006;26:356-537.
22. Barone A, Prascina F, Russo V, Iaculli C, Primavera V, Querques G, et al. Successful treatment of pseudophakic cystoid macular edema with intravitreal bevacizumab. J Cataract Refract Surg 2008;34:1210-1212.
23. Sabet-Peyman EJ, Nguyen QD, Do DV. Cystoid macular edema responds to intravitreal triamcinolone and rebounds after intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging 2009;40:413-415.
24. Spitzer MS, Szurman P, Bartz-Schmidt KU. Intravitreal bevacizumab in postoperative pseudophakic cystoid macular edema: does it really work? J Cataract Refract Surg 2008;34:880.
25. Shelsta HN, Jampol LM. Pharmacologic therapy of pseudophakic cystoid macular edema: 2010 update. Retina 2011;31:4-12.
26. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.